Our study in an experimental murine model for human smallpox suggests that MVA vaccines with inactivated regulatory genes E3L or F1L efficiently prime antigens-specific CD8+ T cells, allow for rapidly protective immunization against a lethal ECTV infection but do not improve the overall protective efficacy of MVA in conventional vaccination against a harsh respiratory ECTV challenge. Here, CD8A is linked to smallpox.